Thrombolytics (tPA, Streptokinase, Urokinase)

Watch Video


Coming soon...

Key Points

  • Thrombolytics (Fibrinolytics)
    • Drug Names
      • Alteplase
        • Also known as tissue plasminogen activator (tpA)
      • Reteplase
      • Tenecteplase
      • Streptokinase
      • Urokinase
    • Mechanism
      • Dissolve clots (thrombi) by activating plasminogen to form plasmin
        • Plasmin cleaves fibrin (fibrinolysis) holding clots together
        • Alteplase and recombinant tpA drugs (reteplase, tenecteplase) are clot-specific and act only on fibrin-bound plasminogen
        • Streptokinase and urokinase are not clot-specific and activate all circulating plasminogen (including that bound to clots)
    • Clinical Use
      • Dissolution of clots/thrombi
        • Ischemic stroke within 3-4.5 hours
        • ST-elevation MI when stenting (PCI) is not available
          • Fibrinolytic drugs are used for treatment of acute myocardial infarction. They are most effective when used within six hours of onset of ST elevation myocardial infarction (Ml). Use of fibrinolytic drugs in properly selected patients of acute ST elevation Ml decreases mortality significantly.
        • Life-threatening pulmonary emboli
    • Laboratory Findings
      • Increased PT and PTT
        • Due to clot dissolution and active cleavage of fibrin
    • Adverse Effects
      • Bleeding
        • High bleeding risk, and should be avoided in patients with risk of intracranial bleeding, recent surgery, severe hypertension, or recent bleeding events
    • Reversal
      • Aminocaproic acid
      • Tranexamic acid